Kiniksa is evaluating the progression of KPL-045, a monoclonal antibody inhibitor of the CD30
ligand co-stimulatory molecule, based on preclinical data from the program in the context of the company's portfolio.
Adcetris is an antibody-drug conjugate directed to CD30
, a defining marker of classical Hodgkin lymphoma and expressed on the surface of several types of peripheral T-cell lymphomas.
Tissue microarrays were then stained with CD137 as well as CD15, CD20, and CD30
and reviewed by 2 pathologists.
LyP is part of a spectrum of CD30
(Ki-1)-positive cutaneous lymphoproliferative diseases (CD30+ LPDs), including lymphomatoid papulosis, primary cutaneous anaplastic large cell lymphoma (pcALCL), and borderline CD30+ lesions.5 The pathophysiology of CD30+ LPDs, including LyP, is largely unknown.6 CD30
signaling is known to have an effect on the growth and survival of lymphoid cells, and one hypothesis is that genetic instability and accumulated genetic defects may have a role in the development of LyP and the progression to associated neoplasms.7
PC-ALCL is a CD30+ lymphoproliferative disorder of the skin consisting of cells with an anaplastic, pleomorphic, or immunoblastic cytomorphology with > 75% of the tumor cells expressing CD30
Eventually the patient underwent left pneumonectomy with final histology including immunohistochemistry demonstrating anaplastic large cell lymphoma positive for CD30
, Ki-67, CD45, and ALK-1 (Figure 4).
Peripheral T-cell lymphomas expressing CD30
Since October 2016, pretransplant determination of the immune activation marker soluble CD30
(sCD30) in ELISA has also become an important component of pretransplant risk estimation in measure 1 of the Heidelberg Algorithm because pretransplant activation of the immune system, as measured by high sCD30 levels, was in two recent studies of 80 presensitized high-risk patients from Heidelberg and 385 presensitized patients from 13 transplant centers (corresponding to a series of some 1000 patients) found to be a substantial risk factor for graft loss in the presence of DSA (see below) [3, 7].
is a member of the tumor necrosis factor/nerve growth factor receptor superfamily , which is preferentially expressed by human T cell clones producing T helper (Th) type 2 cytokines, and can be released in a soluble form (sCD30) by activated cells [8, 9].
It has been listed as a primary, cutaneous, CD30
(+) lymphoproliferative disorder in the current World Health Organization (WHO) and European Organization for Research and Treatment of Cancer (EORTC) classification .
Immunohistochemical analysis demonstrated strong CD30
, CD43, and MUM1 expression, while EMA was weakly positive (Figure 5).